[1] GE Xiaoxiao ZHANG Panpan WU QiongZHANG Xuesong LIANG Liuyan XIE Yundong,.Study on the Toxic Reduction and Mechanism of HuangyaoziCompatibility Based on Liver Injury [J]. Modern Traditional Chinese Medicine, 2023, (03): 1-5. [doi: 10.13424/j.cnki.mtcm.2023.03.001]
Study on the Toxic Reduction and Mechanism of HuangyaoziCompatibility Based on Liver Injury
- Article number:
- 1672-0571(2023)03-0001-05
- Keywords:
- Key words:Huangyaozi; Toxicity; Liver injury; Compatibility; Detoxification
- ZTFLH:
- R285.6
- Code:
- A
- Abstract:
- Abstract：Huangyaozi and its containing preparations have significant effects in the clinical treatment of thyroid diseases,pertussis,esophageal cancer,gastric cancer,and other diseases,with definite therapeutic effects.However,longterm or excessive use of Huangyaozi can lead to liver damage,even liver failure.Clinical and research have found that combining Huangyaozi with other traditional Chineseherbals (such as Angelica sinensis and Schisandra chinensis) can effectively reduce and prevent its damage to the liver.By reviewing relevant materials,this study summarized the relevant research on the compatibility of Huangyaozi with other traditional Chinese herbals to reduce toxicity,in order to summarize the effect and mechanism of Huangyaozis compatibility with other traditional Chinese herbals to reduce toxicity,and provide a basis for the safe and reasonable clinical application of Huangyaozi.
References:
［1］赵艳,王家志.黄药子分离部位的肝脏毒性药理学研究［J］.中医药信息,2008,25(5):30-31,88.
［2］赵许杰,闫雪生,孙丹丹.黄药子的药理作用和临床研究进展［J］.药物评价研究,2012,35(2):147-149.
［3］蒋永福,张焜,赵肃清,等.黄药子肝脏毒性成分的筛选研究［J］.中药材,2009,32(1):107-109.
［4］陈勇,程明,刘春霞.肝脏毒性中药的研究现状与展望［J］.中草药,2004(11):119-121.
［5］王少珍,廖联明.黄药子中毒导致肝损伤的机制研究［J］.中华卫生应急电子杂志,2018,4(1):33-44.
［6］苏莉,朱建华,程利宝,等.亚急性黄药子中毒的实验病理学研究［J］.法医学杂志,2003,19(2):81-83.
［7］陈德煜,禄保平,范普雨.不同剂量黄药子对小鼠血清ALT、AST活性及肝组织病理形态学的影响［J］.中医学报,2013,28(4):541-542,617.
［8］尚兰琴,张洁,郝卫东.黄药子水煎剂灌胃对小鼠的肝毒性及其机制［J］.北京大学学报(医学版),2007,39(2):200-202.
［9］王加志,刘树民,赵艳,等.黄药子醇提物不同处理方式对肝毒性的影响［J］.中医药信息,2009,26(2):21-22,93.
［10］李军,刘晨,王君明,等.黄药子黄独素B活性、毒性及配伍减毒［J］.中国老年学杂志,2019,39(15):3846-3848.
［11］陆霄鹤,武谦虎.黄药子复方制剂致肝损害33例文献分析［J］.四川中医,2014,32(9):162-164.
［12］杜丽霞,罗明媚,刘树民.黄药子现代毒理学研究进展［J］.辽宁中医药大学学报,2007,9(3):71-72.
［13］刘海洋,路瑞华,李伟,等.以离体肝灌流技术研究当归对黄药子肝毒性的保护作用［J］.中医药信息,2012,29(2):104-106.
［14］汤青,刘树民,王加志,等.黄药子及黄药子配伍当归对大鼠肝组织grp78和bad基因表达的影响［J］.药物不良反应杂志,2010,12(2):91-95.
［15］王新华,索晴.黄药子及配伍当归含药血清对肝细胞毒性的实验研究［J］.中国中医药科技,2008,15(6):434-435.
［16］索晴,崔立然,刘树民,等.黄药子及配伍当归后含药血清抗肿瘤作用的研究［J］.中国中医药科技,2008,15(2):113-114.
［17］刘树民,崔立然,于栋华,等.当归对黄药子致肝超微结构损害的保护作用［J］.辽宁中医杂志,2010,37(9):1823-1824.
［18］卓实.黄药子肝毒性及配伍减毒的研究进展［J］.临床合理用药杂志,2011,4(3):150-152.
［19］张莉莉,韦宇,方心怡,等.夏枯草、黄药子、五味子治疗甲状腺功能亢进症经验:仝小林三味小方撷萃［J］.吉林中医药,2020,40(5):568-570.
［20］贾璐,杭薇,徐幸杰,等.五味子乙素通过抑制TLR4/NF-κB信号通路减轻PD小鼠炎症反应及DA能神经元凋亡［J］.中国免疫学杂志,2022,38(4):427-431.
［21］刘素兰.五味子配伍与临床应用［J］.临床合理用药杂志,2012,5(29):66-67.
［22］刘传梦,方静,王元霞,等.中草药相关肝损伤机制研究进展［J］.中华中医药学刊,2020,38(6):177-181.
［23］杨辉,李多娇,王彦云,等.五味子影响黄药子肝肾毒性的实验观察［J］.临床药物治疗杂志,2008,6(1):29-34.
［24］潘云淼,侯晓楠.黄药子肝毒性研究进展［J］.世界最新医学信息文摘(连续型电子期刊),2020,20(10):46-47.
［25］谢敏,龚甜,赵勇,等.黄药子及其组方在甲状腺疾病中的应用［J］.江西中医药,2018,49(11):74-77.
［26］徐敏,卜平,李瑶瑶.半枝莲黄酮类化合物对体外肿瘤血管生成的影响［J］.世界华人消化杂志,2007,15(20):2215-2219.
［27］杜晓翔,陈必成.探讨半枝莲醇提物对小鼠细胞色素P450酶和谷胱甘肽S转移酶活性的影响［J］.中国现代医生,2018,56(11):26-29.
［28］牛成伟,季莉莉,王峥涛.半枝莲对黄药子肝毒性的保护作用及其机制［J］.药学学报,2016,51(3):373379.
［29］田新宇,范翠梅,渠田田,等.半枝莲总黄酮中7种成分的含量测定及抗肿瘤活性［J］.中国实验方剂学杂志,2017,23(1):53-59.
［30］何丹,刘凤琴,李焕德.甘草解毒作用研究进展［J］.中南药学,2009,7(12):927-931.
［31］华碧春,卓实,史道华,等.甘草减轻黄药子肝毒性的研究［J］.福建中医药大学学报,2013,23(1):23-25.
［32］华碧春,胡娟,王瑞国,等.甘草降低黄药子致小鼠肝毒性的实验研究［J］.世界中西医结合杂志,2011,6(1):24-27.
［33］范金晶,华碧春,刘娇,等.甘草减轻黄药子对大鼠肾毒性的实验研究［J］.医学研究杂志,2014,43(9):31-33.
［34］牛成伟,陆宾,季莉莉,等.黄独素B诱导小鼠急性肝损伤及其机制［J］.中国中药杂志,2014,39(7):1290-1292.
［35］Wang JM,Sheng YC,Ji LL,等.阿魏酸降低黄独素B肝毒性并提高其抗肿瘤活性［J］.Journal of Zhejiang UniversityScience B (Biomedicine ＆ Biotechnology),2014,15(6):540-547.
［36］Wang JM,Liang QN,Ji LL,et al.Genderrelated difference in liver injury induced by Dioscorea bulbifera L.rhizome in mice［J］.Human & Experimental Toxicology,2011,30(9):1333-1341.
［37］Niu CW,Sheng YC,Yang R,et al.Scutellarin protects against the liver injury induced by diosbulbin B in mice and its mechanism［J］.Journal of Ethnopharmacology,2015,164:301-308.
［38］侯小涛,戴航,周江煜.黄柏的药理研究进展［J］.时珍国医国药,2007,18(2):498-500.
［39］龚淼.黄柏的化学成分和药理作用研究［J］.中国医院用药评价与分析,2009,9(4):318-320.
［40］王秋红,杨欣,王蒙,等.黄芩与黄柏协同保护黄药子致肝毒性的实验研究［J］.中国中药杂志,2016,41(5):898-903.
［41］王君明,雷军锋,季莉莉,等.基于以抗肿瘤为主要活性的黄药子毒性研究进展及对策［J］.中国实验方剂学杂志,2011,17(12):256-259.
［42］巴明玉,余丹丹,王娴,等.燕树勋应用黄药子治疗甲状腺疾病经验［J］.河南中医,2021,41(5):719-721.
Memo
基金项目：国家自然科学基金项目（82204790）；陕西省自然科学基础研究计划项目（2021JQ730）；陕西省教育厅专项科研计划项目（21JK0598）